Epinephrine Sublingual Film Gets Fast Track Status for Anaphylaxis
AQST-108 is a sublingual film that delivers systemic epinephrine utilizing the Company’s proprietary technology.
Allergic Disorders
Adolescents Who Use E-Cigarettes, Marijuana May Have Higher Odds of Lifetime Asthma
Electronic cigarette use is associated with lifetime asthma in US adolescents, and may become more damaging when combined with marijuana or cigarette smoking.
MPR Weekly Dose Podcast Episode 46
This week there’s more COVID vaccine developments; A first-of-its-kind trial assessing a drug for preventing COVID in long term care facilities; A cannabidiol treatment gains another indication; Depression treatment gains indication for major depressive disorders with acute suicidal ideation or behavior; And the FDA requests more information for their review of the peanut allergy treatment, Viaskin.
Bisphenol A Linked to More Asthma Symptoms in Young Boys
Study shows exposure to bisphenol A is associated with more asthma symptoms in low-income boys.
FDA Wants More Data on Viaskin Peanut Allergy Patch
The FDA noted that it could not approve the BLA due to concerns regarding “the impact of patch-site adhesion on efficacy and indicated the need for patch modifications, and subsequently a new human factor study.”
Pharmacologic Ingredients in OTC Sinonasal Products Often Redundant
The same 8 nonanalgesic active ingredients were found in hundreds of brand name over-the-counter sinonasal products.
FDA: Certain Epinephrine Autoinjector Devices May Have Missing Safety Component
Certain lots of Amneal’s Epinephrine Injection, Autoinjector 0.3mg may not contain the yellow “stop collar” that is necessary for proper dosing of the anaphylaxis treatment, according to the FDA.
Discontinuing Mepolizumab Decreases Asthma Control, Increases Eosinophil Counts
Patients with severe eosinophilic asthma who are treated with mepolizumab and subsequently stop treatment have increased blood eosinophil counts and increased exacerbations, among other negative clinical outcomes.
Boxed Warning Added to Montelukast Labeling Regarding Neuropsychiatric Events
Because the benefits of montelukast may not outweigh the potential risk of neuropsychiatric symptoms in patients with allergic rhinitis, use should be reserved for patients who have an inadequate response or intolerance to alternative therapies.
Zerviate Ophthalmic Solution Now Available for Allergic Conjunctivitis
Eyevance announced the launch of Zerviate™ (cetirizine ophthalmic solution) 0.24% for the treatment of ocular itching associated with allergic conjunctivitis in patients 2 years of age and older.
